Granisetron Transdermal Patch System for Prevention of CINV by CapeOX

Inclusion Criteria:

• Male or female, aged >18 years.
• Eligible patients were diagnosed with a colorectal malignancy and scheduled to receivechemotherapy of CapeOx regimens.
• The Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores of patientswere between 0 and 2.
• Patients with life expectancy≥6 months.
• Patients with the ability to understand the study and are willing to sign writteninformed consent document.
• Patients who were able to read, understand and follow the study procedures，andcompleted the questionnaire unaided.

Exclusion Criteria:

• Patients with metabolic and haematological abnormalities who are unsuitable forchemotherapy. The following criteria are included: (1) Abnormal of blood routine:absolute neutrophil count(ANC) <1.5109/L，white blood cell count (WBC)<3.0109/L,platelet count (PLT) <100109/L or hemoglobin (HB)<100g/L;(2) Abnormal liver function:aspartate aminotransaminase (AST) and/or aspartate aminotransferase (ALT)≥2.5ULN,bilirubin is greater than 1.5 times the upper limit of normal value (ULN). In patientswith known liver metastasis: AST is greater than or equal to 5 times the upper limitof normal value (ULN); ALT is greater than or equal to 5 times the upper normal value (ULN); (3) Abnormal renal function: serum creatinine is greater than 1.5*ULN.
• Patient had symptomatic primary or metastatic central nervous system malignancies.
• Patient used any drug with potential antiemetic effect within 7 days before receivingchemotherapy: 5-HT3 receptor antagonist (such as granisetron), phenothiazide (such aschlorpromazine), phenylbutanone (such as haloperidol), benzamide (such asmetoclopramide), domperidone, cannabinoids, herbal medicine with potential antiemeticeffect, anisodamine, seclizine, etc.
• Patients began to receive benzodiazepines or opioids within 48 hours before the firstday of the study (except for single daily use of triazolam, temazepam or midazolam).
• Patients shall not receive any dose of systemic glucocorticoid treatment within 72hours before the first day, except as specified in the protocol.
• Patients with historical or predisposing cardiac conduction abnormalities (such astorsade de pointe, ventricular tachycardia, long QT interval syndrome, or others),excluding incomplete right bundle branch block.
• Patients with severe cardiovascular diseases include acute myocardial infarction,unstable angina pectoris, significant membranous or pericardial disease, history ofventricular tachycardia, symptomatic chronic heart failure (New York Heart Association [NYHA] class III-IV) and uncontrolled hypertension.
• Patients with severe emotional or mental disorders.
• Patients are taking or has used the following CYP3A4 inducers within 30 days beforethe first day of treatment, which will affect the efficacy of therapeutic drugsaccording to the evaluation of the researcher.
• Patients are taking or has used the following CYP3A4 substrates and inhibitors within 7 days before the first day of treatment, which will significantly increase theadverse events related to therapeutic drugs according to the evaluation of theinvestigator.
• Patients with active phase infection (e.g. pneumonia) or any uncontrolled disease (such as diabetic ketoacidosis or gastrointestinal obstruction), researchers believethat treatment may confuse research results or lead to uncertainty risk.
• Pregnant women, lactating women, or women of childbearing age with positive bloodand/or urine HCG test results before the test. Male and female subjects did not takeeffective contraceptive measures, or planned to be pregnant within 6 months after thestart of the trial.
• Patients have any medical history that the investigator believes may confound theresults of the study or expose the patient to unnecessary risks.